Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2021-01-14 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled '定期现场检查报告' which translates to 'Periodic On-site Inspection Report'. It is issued by a sponsoring institution (安信证券股份有限公司) regarding the company 泰林生物. The content includes detailed checklists and compliance verification related to corporate governance, internal control, information disclosure, use of raised funds, performance, and other regulatory compliance aspects. The document is a report of an inspection conducted over a specific period (2020年度) and dates of inspection (2021年1月7日~2021年1月9日) are provided. The document length is 3104 characters, which is relatively short but contains substantive content of an audit/inspection nature rather than a mere announcement or certification. It is not an annual or interim financial report, nor a management discussion or earnings release. It is a standalone audit/inspection report focusing on compliance and internal controls, fitting the category of Audit Report / Information (AR). FY 2020
2021-01-14 Chinese
安信证券股份有限公司关于公司持续督导期2020年度培训情况报告
Audit Report / Information Classification · 90% confidence The document is a report from Anxin Securities regarding the 2020 annual training conducted for Zhejiang Tailin Biotechnology Co., Ltd. during the continuous supervision period related to its IPO and listing on the Shenzhen Stock Exchange. It details the training content, personnel involved, and outcomes, focusing on regulatory compliance and operational standards. The document is a formal report on training activities rather than a financial report, audit, or announcement of voting results. It does not fit into categories like Annual Report, Interim Report, or Regulatory Filings. It is a specialized report related to ongoing supervision and training by the sponsor institution, which aligns best with Audit Report / Information (AR) as it relates to regulatory compliance and supervisory activities rather than financial results or governance changes. FY 2020
2021-01-14 Chinese
首次公开发行前已发行股份上市流通提示性公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement regarding the lifting of restrictions on previously issued shares before the company's initial public offering (IPO) and their subsequent listing and circulation. It includes specifics about the number of shares, shareholders involved, their commitments, lock-up periods, and compliance with regulatory requirements. The document references regulatory approvals from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it discusses shareholder commitments and restrictions related to share transfers and price stabilization measures. This type of document is typically classified as a Regulatory Filing (RNS) because it is an official regulatory announcement about share circulation and compliance, not a financial report, earnings release, or management report. It is also not a report publication announcement since it contains substantive detailed information rather than just announcing a report's release.
2021-01-11 Chinese
安信证券股份有限公司关于公司首次公开发行股票限售股解禁并上市流通的核查意见
Capital/Financing Update Classification · 95% confidence The document is a detailed verification opinion from a sponsoring securities company regarding the unlocking and listing of restricted shares following the company's initial public offering (IPO). It references regulatory approvals, shareholder commitments, shareholding changes, and compliance with stock exchange rules. The content focuses on the release of restricted shares and their circulation in the market, including commitments by directors and senior management about shareholding and lock-up periods. This type of document is typical of a Capital/Financing Update, specifically related to share lock-up release and listing of shares post-IPO. It is not an annual report, earnings release, or a general regulatory filing, but a specific update on capital structure and share circulation. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length and detail support this classification with high confidence.
2021-01-11 Chinese
前次募集资金使用情况鉴证报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "前次募集资金使用情况鉴证报告" which translates to "Previous Fundraising Use Verification Report" and includes detailed sections on the use of previously raised funds, their storage, changes in use, and investment project performance. It references compliance with regulations from the China Securities Regulatory Commission regarding fundraising use reports. The document includes an auditor's verification report, detailed financial tables on fundraising amounts, usage, and project investment returns. The content is focused on the use and verification of previously raised capital, which aligns with a Capital/Financing Update rather than a full Annual Report or Audit Report. It is not a brief announcement or a certification letter but a substantive report on fundraising use and verification. Therefore, the most appropriate classification is Capital/Financing Update (CAP).
2021-01-08 Chinese
向不特定对象发行可转换公司债券预案
Capital/Financing Update Classification · 95% confidence The document is titled as a "向不特定对象发行可转换公司债券预案" which translates to "Proposal for the Private Placement of Convertible Bonds to Unspecified Objects." It contains detailed information about the issuance of convertible bonds, including terms, conditions, issuance scale, interest rates, conversion prices, redemption clauses, and use of proceeds. It also includes financial statements such as consolidated balance sheets, profit and loss statements, and cash flow statements for multiple years, indicating substantive financial data and analysis. The document is a detailed plan and disclosure related to a capital raising activity through convertible bonds issuance. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and financing activities. The document length is substantial (15,000 characters), and it is not merely an announcement or a brief summary but a full proposal with financial data. Therefore, the correct classification is CAP with high confidence.
2021-01-08 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.